Abstract
The neurotrophic factors play an important role in the maintenance of neurone viability and neuronal communication which are considered to be altered in schizophrenia. Subchronic application of ketamine (Ket) was found to be a useful model in schizophrenia research. To further validate this model the mRNA levels of neurotrophic factors NGF, NT- 3, and BDNF and their receptors TrkA, TrkB, and TrkC, respectively, were measured in different brain areas in Ketpretreated rats subchronically dosed with the atypical antipsychotic drug risperidone (Ris). With the exception of NGF in the frontal cortex, Ket pretreatment did change NGF, NT-3, and BDNF mRNA levels in the frontal cortex, the hippocampus, the striatum, the thalamus/hypothalamus region, and in the cerebellum. These changes correspond with changes at their tyrosine kinase receptors. Ris treatment normalised altered NT-3 levels in the hippocampus and balanced BDNF levels in the same structure. It was concluded that the Ket model might reflect distinct alterations in neurotrophic factor activity as found in schizophrenic patients and, moreover, that Ris treatment rebalances disturbed neurotrophic factor activity.
Keywords: Schizophrenia, ketamine, risperidone, neurotrophic factors, rat
Medicinal Chemistry
Title: Expression of mRNA of Neurotrophic Factors and their Receptors are Significantly Altered After Subchronic Ketamine Treatment
Volume: 4 Issue: 3
Author(s): Axel Becker, Gisela Grecksch, Herbert Schwegler and Thomas Roskoden
Affiliation:
Keywords: Schizophrenia, ketamine, risperidone, neurotrophic factors, rat
Abstract: The neurotrophic factors play an important role in the maintenance of neurone viability and neuronal communication which are considered to be altered in schizophrenia. Subchronic application of ketamine (Ket) was found to be a useful model in schizophrenia research. To further validate this model the mRNA levels of neurotrophic factors NGF, NT- 3, and BDNF and their receptors TrkA, TrkB, and TrkC, respectively, were measured in different brain areas in Ketpretreated rats subchronically dosed with the atypical antipsychotic drug risperidone (Ris). With the exception of NGF in the frontal cortex, Ket pretreatment did change NGF, NT-3, and BDNF mRNA levels in the frontal cortex, the hippocampus, the striatum, the thalamus/hypothalamus region, and in the cerebellum. These changes correspond with changes at their tyrosine kinase receptors. Ris treatment normalised altered NT-3 levels in the hippocampus and balanced BDNF levels in the same structure. It was concluded that the Ket model might reflect distinct alterations in neurotrophic factor activity as found in schizophrenic patients and, moreover, that Ris treatment rebalances disturbed neurotrophic factor activity.
Export Options
About this article
Cite this article as:
Becker Axel, Grecksch Gisela, Schwegler Herbert and Roskoden Thomas, Expression of mRNA of Neurotrophic Factors and their Receptors are Significantly Altered After Subchronic Ketamine Treatment, Medicinal Chemistry 2008; 4 (3) . https://dx.doi.org/10.2174/157340608784325124
DOI https://dx.doi.org/10.2174/157340608784325124 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transgenic C. elegans as a Model in Alzheimers Research
Current Alzheimer Research Pathology of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Conformational Diseases: Structural Studies of Aggregation of Polyglutamine Proteins
Current Computer-Aided Drug Design A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome
CNS & Neurological Disorders - Drug Targets Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy P2X4 Receptors of Microglia in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
Current Alzheimer Research Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging Survey of Functional Activities of Alpha-fetoprotein Derived Growth Inhibitory Peptides: Review and Prospects
Current Protein & Peptide Science Toward a Developmentally Centered Approach to Adolescent Alcohol and Substance Use Treatment
Current Drug Abuse Reviews Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets